IQVIA Holdings Inc. (NYSE:IQV) Stake Reduced by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 202,170 shares of the medical research company’s stock after selling 26,885 shares during the quarter. IQVIA comprises about 1.6% of Hardman Johnston Global Advisors LLC’s investment portfolio, making the stock its 19th largest holding. Hardman Johnston Global Advisors LLC owned about 0.11% of IQVIA worth $39,728,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Capital Performance Advisors LLP acquired a new position in IQVIA during the 3rd quarter valued at about $27,000. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth approximately $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. increased its position in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, Concord Wealth Partners acquired a new position in IQVIA during the 3rd quarter worth $57,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.6 %

Shares of NYSE:IQV opened at $190.94 on Monday. The firm has a 50 day simple moving average of $199.57 and a 200 day simple moving average of $216.25. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $33.62 billion, a PE ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Truist Financial reissued a “buy” rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft dropped their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.